SCHEMBL23958196

SCHEMBL23958196

COc1cccc(-n2c(Nc3cccnc3)nc3ccc(F)cc3c2=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.49
ADORA1 P30542 1/20 0.49
ABCG2 Q9UNQ0 4/20 0.46
ABCB1 P08183 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 2/20 0.45
USP2 O75604 2/20 0.45
CYP1A2 P05177 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
CYP19A1 P11511 1/20 0.43
HTR7 P34969 2/20 0.43
PIK3CD O00329 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24110985 0.91 G6PD (0.50) ABCG2MEN1USP2CYP1A2KMT2A
SCHEMBL23958161 0.91 PIK3CD (0.43) ADORA2AADORA1ABCG2ABCB1MEN1
SCHEMBL24110807 0.90 PIK3CD (0.45) ABCG2PIK3CD
SCHEMBL24111023 0.89 PSD (0.50) SMN1; SMN2ALDH1A1TSHRPIK3CDTP53
SCHEMBL23958245 0.88 PIK3CD (0.50) CYP1A2KMT2AALDH1A1PIK3CD
SCHEMBL29738614 0.88 PIK3CD (0.46) ABCG2KMT2APIK3CDPOLB
SCHEMBL30103245 0.88 PIK3CD (0.50) CYP1A2KMT2AALDH1A1PIK3CD
SCHEMBL23958265 0.88 PIK3CD (0.46) ABCG2KMT2APIK3CDPOLB
SCHEMBL24110982 0.87 PIK3CD (0.43) CYP19A1HTR7PIK3CDMIF
SCHEMBL24110979 0.87 CYP19A1 (0.52) ABCG2ABCB1SMN1; SMN2MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed
WO-2021215537-A1 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 (JP) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 ADORA2A 779/4885ADORA1 605/4885ABCG2 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.